INSIGHTS ON CLINICAL TRIAL TECHNOLOGIES

• Clinical Trial Data Quality In Neurology Studies

  Discover how standardized ocular biomarkers and point-of-need delivery safeguard data integrity in complex neurology trials while keeping patients engaged.

• Future Of AI Analytics In Chronic Pain And Neurological Research

  This presentation explores how digital health tools and AI diagnostics are transforming clinical research, driving accurate evaluations and faster therapy development for chronic pain and neurological disorders.

• Navigating The Post-Capture Era Of Clinical Trials

  Liberating data through structured workflow management is the key to evolving clinical trials from a series of administrative hurdles into a high-speed engine for medical innovation.

• State of Materiovigilance: Gaps, Technology & Outsourcing

  Explore how pharma and biotech companies are using AI, outsourcing, and new technologies to strengthen materiovigilance for complex drug-device products.

• Rave RTSM Vs Traditional IRT: User Persective

  12/2/2024

  Examine the differences between Traditional IRT and Rave RTSM, highlighting key attributes like workflow integration, user management, and overall impact on clinical trial operations.

• FDA Pushes For Patient Voice: ePRO In Oncology Trials

  1/8/2026

  FDA urges sponsors and CROs to include patient voices in oncology trials. Discover why it matters and how to start integrating this approach.

• Customizing EDC Workflows For Specialty Pharma, Rare Disease Trials

  10/9/2025

  Rare disease and specialty pharma trials demand a level of flexibility with electronic data capture systems that can adapt dynamically without sacrificing data integrity.

• Future Predictions For Clinical Technologies

  8/11/2025

  In 2025, sponsors are prioritizing configurable, interoperable solutions that integrate seamlessly across IRT, eCOA, CTMS, eConsent, and supply chain systems.

• What The Joint FDA And EMA's AI Principles Can Mean For Clinical Trial Technology

  5/6/2026

  New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.